Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Documenti analoghi

• Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
  di: Johnson, Melissa L., et al.
  Pubblicazione: (2011)
• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2010)
• Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Lung Cancers
  di: Yu, Helena A., et al.
  Pubblicazione: (2013)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  di: Chaft, Jamie E., et al.
  Pubblicazione: (2011)
• Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
  di: Yu, Helena A., et al.
  Pubblicazione: (2014)